Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases

About 40% of patients with non-small cell lung cancer (NSCLC) develop brain metastases (BMs) throughout the disease, and the occurrence of BMs is considered to have a fairly high mortality rate. Therefore, the management of brain metastases in NSCLC patients is a clinical challenge. Currently, multidisciplinary diagnosis and treatment methods are often used to achieve effective control of intracranial disease and prolong survival. Immunotherapy (IT) is one of the core therapies for NSCLC. Single or combined IT represented by immune checkpoint inhibitors(ICIs) of programmed death-1(PD-1)/ programmed cell death-ligand 1 (PD-L1) can significantly improve the prognosis of patients with advanced NSCLC.ICIs has been shown to be safe and effective in patients with BMs, although patients with BMs are mostly underrepresented in randomized clinical trials. In this review, we summarized the mechanism of ICIs in the treatment of BMs, and the clinical research and treatment progress of ICIs and their combination with other therapies in patients with BMs s from NSCLC.

Automated summary

About 40% of NSCLC patients develop brain metastases, which have a high mortality rate. The management of brain metastases in NSCLC patients is a clinical challenge. Immunotherapy, particularly immune checkpoint inhibitors, has shown effectiveness in improving the prognosis of advanced NSCLC patients, including those with brain metastases. This review summarizes the mechanism and clinical research progress of immunotherapy in treating brain metastases in NSCLC patients.